SK283088B6 - Spôsob získania antigénu, ktorý imunologicky reaguje s protilátkami proti B burgdorferi antigénom a spôsob výroby vakcíny obsahujúcej takýto antigén - Google Patents
Spôsob získania antigénu, ktorý imunologicky reaguje s protilátkami proti B burgdorferi antigénom a spôsob výroby vakcíny obsahujúcej takýto antigén Download PDFInfo
- Publication number
- SK283088B6 SK283088B6 SK1510-98A SK151098A SK283088B6 SK 283088 B6 SK283088 B6 SK 283088B6 SK 151098 A SK151098 A SK 151098A SK 283088 B6 SK283088 B6 SK 283088B6
- Authority
- SK
- Slovakia
- Prior art keywords
- antigen
- burgdorferi
- mice
- ospa
- antibody
- Prior art date
Links
- 208000016604 Lyme disease Diseases 0.000 title abstract description 17
- 229960005486 vaccine Drugs 0.000 title abstract description 7
- 239000000427 antigen Substances 0.000 claims abstract description 58
- 102000036639 antigens Human genes 0.000 claims abstract description 58
- 108091007433 antigens Proteins 0.000 claims abstract description 58
- 241000589969 Borreliella burgdorferi Species 0.000 claims abstract description 49
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 108700006640 OspA Proteins 0.000 claims abstract description 5
- 239000000945 filler Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 17
- 241000448699 Borrelia burgdorferi ZS7 Species 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 7
- 230000002163 immunogen Effects 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 3
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 3
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 3
- 239000012050 conventional carrier Substances 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims description 2
- 229940042470 lyme disease vaccine Drugs 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000008105 immune reaction Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 abstract description 3
- 239000000969 carrier Substances 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 34
- 208000015181 infectious disease Diseases 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 210000001503 joint Anatomy 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 206010003246 arthritis Diseases 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000589970 Spirochaetales Species 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 241000238876 Acari Species 0.000 description 4
- 206010062746 Carditis Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010040721 Flagellin Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000009525 Myocarditis Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 208000021646 inflammation of heart layer Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 208000018937 joint inflammation Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000276440 Borrelia burgdorferi B31 Species 0.000 description 2
- 241001288713 Escherichia coli MC1061 Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100039352 Immunoglobulin heavy constant mu Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- WHLPIOPUASGRQN-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C WHLPIOPUASGRQN-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229940099789 ospa protein Drugs 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 241001552669 Adonis annua Species 0.000 description 1
- 108010039206 Biotinidase Proteins 0.000 description 1
- 102100026044 Biotinidase Human genes 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 241000238681 Ixodes Species 0.000 description 1
- 241001480843 Ixodes ricinus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3931236 | 1989-09-19 | ||
DE4015911A DE4015911A1 (de) | 1989-09-19 | 1990-05-17 | Impfstoff gegen die lyme-krankheit |
Publications (2)
Publication Number | Publication Date |
---|---|
SK151098A3 SK151098A3 (en) | 1999-04-13 |
SK283088B6 true SK283088B6 (sk) | 2003-02-04 |
Family
ID=25885304
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1510-98A SK283088B6 (sk) | 1989-09-19 | 1990-09-19 | Spôsob získania antigénu, ktorý imunologicky reaguje s protilátkami proti B burgdorferi antigénom a spôsob výroby vakcíny obsahujúcej takýto antigén |
SK1511-98A SK283089B6 (sk) | 1989-09-19 | 1990-09-19 | Patogénny mikroorganizmus B.burgdorferi a spôsob jeho izolácie a rekultivácie |
SK4560-90A SK280285B6 (sk) | 1989-09-19 | 1990-09-19 | Očkovacia látka proti borelióze a spôsob jej výrob |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1511-98A SK283089B6 (sk) | 1989-09-19 | 1990-09-19 | Patogénny mikroorganizmus B.burgdorferi a spôsob jeho izolácie a rekultivácie |
SK4560-90A SK280285B6 (sk) | 1989-09-19 | 1990-09-19 | Očkovacia látka proti borelióze a spôsob jej výrob |
Country Status (24)
Country | Link |
---|---|
US (6) | US5178859A (fr) |
EP (5) | EP0633028B1 (fr) |
JP (3) | JP3205932B2 (fr) |
KR (2) | KR100205462B1 (fr) |
AT (4) | ATE175576T1 (fr) |
AU (1) | AU651560B2 (fr) |
CA (1) | CA2025597C (fr) |
CZ (2) | CZ284616B6 (fr) |
DE (5) | DE4015911A1 (fr) |
DK (4) | DK0418827T3 (fr) |
ES (4) | ES2082812T3 (fr) |
FI (1) | FI102248B (fr) |
GR (3) | GR3018995T3 (fr) |
HK (2) | HK1002405A1 (fr) |
HR (1) | HRP940545B1 (fr) |
HU (2) | HU212716B (fr) |
IE (1) | IE903377A1 (fr) |
NO (2) | NO311767B1 (fr) |
NZ (1) | NZ235260A (fr) |
PL (2) | PL169804B1 (fr) |
PT (1) | PT95349B (fr) |
SI (1) | SI9011773B (fr) |
SK (3) | SK283088B6 (fr) |
YU (2) | YU48250B (fr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK590288D0 (da) | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
WO1993008306A1 (fr) * | 1991-10-22 | 1993-04-29 | Symbicom Aktiebolag | AMELIORATION DANS LE DIAGNOSTIC ET LA PROPHYLAXIE DE LA BORRELIOSE PROVOQUEE PAR $i(BORRELIA BURGDORFERI) |
US7094391B1 (en) * | 1988-10-24 | 2006-08-22 | The University Of Texas System | Compositions and methods for administering Borrelia burgdorferi antigens |
US5777095A (en) * | 1988-10-24 | 1998-07-07 | Symbicom Aktiebolag | Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90 |
US6143872A (en) * | 1988-10-24 | 2000-11-07 | Symbicom Aktiebolag | Borrelia burdorferi Osp A and B proteins and immunogenic peptides |
DE4015911A1 (de) * | 1989-09-19 | 1991-03-28 | Max Planck Gesellschaft | Impfstoff gegen die lyme-krankheit |
US5582829A (en) * | 1990-04-05 | 1996-12-10 | Rx Technologies, Inc. | Sonicated borrelia burgdorferi vaccine |
CA2084413A1 (fr) * | 1990-06-15 | 1991-12-16 | Richard A. Flavell | Compositions et methodes pour la prevention et le diagnostic de la maladie de lyme |
DK0465204T3 (da) * | 1990-07-06 | 2000-10-09 | American Home Prod | Vaccine mod Lyme sygdom |
CA2057536C (fr) * | 1990-12-21 | 1999-10-26 | John J. Dunn | Clonage et expression des lipoproteines de borrelia |
US6221363B1 (en) * | 1991-07-11 | 2001-04-24 | Baxter Aktiengesellschaft | Vaccine for the prevention of lyme disease |
US6872550B1 (en) | 1991-07-11 | 2005-03-29 | Baxter Vaccine Ag | Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens |
CA2115554A1 (fr) * | 1991-08-15 | 1993-03-04 | Yves Lobet | Proteines osp-a de sous-groupes de borrelia burgdorferi, genes codant pour ces proteines et vaccins en contenant |
US6676942B1 (en) | 1991-08-15 | 2004-01-13 | Smithkline Beecham Biologicals (S.A.) | Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
JPH06511154A (ja) * | 1991-10-18 | 1994-12-15 | コノート ラボラトリーズ インコーポレイテッド | 組換えBorreliaタンパクの製造法 |
US6303129B1 (en) * | 1992-07-28 | 2001-10-16 | Rx Technologies | Production of borrelia burgdorferi vaccine, product produced thereby and method of use |
US5656451A (en) * | 1993-07-30 | 1997-08-12 | Yale University | OspE, OspF, and S1 polypeptides in borrelia burgdorferi |
US6716591B1 (en) | 1993-07-30 | 2004-04-06 | Yale University | B. burgdorferi polypeptides |
US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
US5558993A (en) * | 1994-06-17 | 1996-09-24 | The Regents Of The University Of California | Cloned Borrelia burgdorferi virulence protein |
GB9511909D0 (en) * | 1995-06-12 | 1995-08-09 | Microbiological Res Authority | Vaccine |
AU2191597A (en) | 1996-02-21 | 1997-09-10 | Board Of Regents, The University Of Texas System | Vmp-like sequences of pathogenic borrelia |
DE19632862B4 (de) | 1996-08-14 | 2006-08-03 | Mikrogen Molekularbiologische Entwicklungs-Gmbh | Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe |
US6458555B1 (en) * | 1996-08-21 | 2002-10-01 | Gerd Bach | Cytologic method of examining mucous membranes |
US6060082A (en) * | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
DE19740735A1 (de) * | 1997-09-16 | 1999-03-18 | Max Planck Gesellschaft | Arzneimittel zur Therapie einer manifesten Lyme-Borreliose |
US6306623B1 (en) | 1998-02-24 | 2001-10-23 | The University Of California | Leptospiral major outer membrane protein LipL32 |
WO2000006745A1 (fr) | 1998-07-31 | 2000-02-10 | Gundersen Lutheran Medical Foundation, Inc. | UTILISATIONS, EN TANT QUE VACCIN, D'EPITOPE(S) BORRELIACIDAL DE PROTEINE C DE SURFACE EXTERIEURE (OSPC) DE $i(BORRELIA BURGDORFERI) |
WO2000056298A2 (fr) * | 1999-03-19 | 2000-09-28 | Luitpold Pharmaceuticals, Inc. | Traitement de la maladie de la lyme au moyen de formulations de glycosaminoglycans polysulfates |
US6592875B1 (en) | 1999-06-21 | 2003-07-15 | Milkhaus Laboratory, Inc. | Method for treatment of lyme disease |
ATE381575T1 (de) | 2000-08-18 | 2008-01-15 | Univ New York State Res Found | Veränderte borrelia burgdorferi ospa |
WO2004058181A2 (fr) | 2002-12-20 | 2004-07-15 | Board Of Regents, The University Of Texas System | Sequences d'especes et de souches de borrelia pathogene de type vmp |
RU2460538C2 (ru) | 2006-11-03 | 2012-09-10 | Шеринг-Плоу Лтд. | Вакцина против лаймской болезни собак |
EP2361930A3 (fr) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia |
EP2167537A2 (fr) | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Procedes compiles pour analyser et trier des echantillons |
WO2009039854A2 (fr) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose |
DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
WO2010037402A1 (fr) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Vaccins moléculaires contre les maladies infectieuses |
US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
WO2011063003A2 (fr) * | 2009-11-17 | 2011-05-26 | Abaxis, Inc. | Peptides et procédés pour la détection d'anticorps contre la maladie de lyme |
US8758772B2 (en) | 2011-11-04 | 2014-06-24 | Abaxis, Inc. | Peptides and methods for the detection of lyme disease antibodies |
PL223175B1 (pl) | 2012-10-22 | 2016-10-31 | Inst Chemii Bioorganicznej Polskiej Akademii Nauk | Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie |
US9610336B1 (en) * | 2014-07-16 | 2017-04-04 | Amiram Katz | Immunotherapy for lyme disease |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK590288D0 (da) * | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
US4772464A (en) | 1985-08-01 | 1988-09-20 | Miles Laboratories, Inc. | Protective antibodies to serotypic determinants of flagellar antigens |
US4888276A (en) | 1986-06-26 | 1989-12-19 | Minnesota Mining And Manufacturing Company | Method and composition for the diagnosis of Lyme disease |
US4721617A (en) | 1986-08-14 | 1988-01-26 | Regents Of The University Of Minnesota | Vaccine against lyme disease |
US5034515A (en) * | 1987-09-22 | 1991-07-23 | Wisconsin Alumni Research Foundation | Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use |
DE4015911A1 (de) * | 1989-09-19 | 1991-03-28 | Max Planck Gesellschaft | Impfstoff gegen die lyme-krankheit |
CA2072008C (fr) * | 1989-12-22 | 2003-01-28 | Renate Fuchs | Proteines a activite immunologique provenant de borrelia burgdorferi, trousses de dosage contenant ces proteines et permettant la detection d'anticorps dans des milieux liquides, et utilisation de ces proteines comme vaccins contre les infections causees par differentes souches de borrelia |
CA2084413A1 (fr) * | 1990-06-15 | 1991-12-16 | Richard A. Flavell | Compositions et methodes pour la prevention et le diagnostic de la maladie de lyme |
DK0465204T3 (da) * | 1990-07-06 | 2000-10-09 | American Home Prod | Vaccine mod Lyme sygdom |
CA2057536C (fr) * | 1990-12-21 | 1999-10-26 | John J. Dunn | Clonage et expression des lipoproteines de borrelia |
CA2115554A1 (fr) * | 1991-08-15 | 1993-03-04 | Yves Lobet | Proteines osp-a de sous-groupes de borrelia burgdorferi, genes codant pour ces proteines et vaccins en contenant |
EP0642574B1 (fr) * | 1991-08-27 | 1998-12-09 | Novo Nordisk A/S | Compositions pour detergents |
JPH06511154A (ja) * | 1991-10-18 | 1994-12-15 | コノート ラボラトリーズ インコーポレイテッド | 組換えBorreliaタンパクの製造法 |
EP0625052A4 (fr) * | 1991-10-21 | 1995-07-19 | Medimmune Inc | Vecteurs d'expression bacteriens contenant de l'adn codant des signaux de secretion de lipoproteines. |
-
1990
- 1990-05-17 DE DE4015911A patent/DE4015911A1/de not_active Withdrawn
- 1990-09-07 HU HU905816A patent/HU212716B/hu not_active IP Right Cessation
- 1990-09-11 NZ NZ235260A patent/NZ235260A/xx unknown
- 1990-09-12 AU AU62444/90A patent/AU651560B2/en not_active Ceased
- 1990-09-18 AT AT94112143T patent/ATE175576T1/de not_active IP Right Cessation
- 1990-09-18 DK DK90117943.2T patent/DK0418827T3/da active
- 1990-09-18 IE IE337790A patent/IE903377A1/en not_active IP Right Cessation
- 1990-09-18 AT AT94112144T patent/ATE191499T1/de not_active IP Right Cessation
- 1990-09-18 DK DK94112145T patent/DK0633028T3/da active
- 1990-09-18 NO NO19904062A patent/NO311767B1/no unknown
- 1990-09-18 EP EP94112145A patent/EP0633028B1/fr not_active Expired - Lifetime
- 1990-09-18 ES ES90117943T patent/ES2082812T3/es not_active Expired - Lifetime
- 1990-09-18 CA CA002025597A patent/CA2025597C/fr not_active Expired - Fee Related
- 1990-09-18 AT AT94112145T patent/ATE186646T1/de not_active IP Right Cessation
- 1990-09-18 DK DK94112143T patent/DK0643974T3/da active
- 1990-09-18 EP EP90117943A patent/EP0418827B1/fr not_active Expired - Lifetime
- 1990-09-18 EP EP98105444A patent/EP0861664A3/fr not_active Withdrawn
- 1990-09-18 AT AT90117943T patent/ATE131732T1/de not_active IP Right Cessation
- 1990-09-18 ES ES94112145T patent/ES2141182T3/es not_active Expired - Lifetime
- 1990-09-18 SI SI9011773A patent/SI9011773B/sl not_active IP Right Cessation
- 1990-09-18 DE DE59009978T patent/DE59009978D1/de not_active Expired - Fee Related
- 1990-09-18 FI FI904597A patent/FI102248B/fi not_active IP Right Cessation
- 1990-09-18 PL PL90286918A patent/PL169804B1/pl not_active IP Right Cessation
- 1990-09-18 DE DE59010863T patent/DE59010863D1/de not_active Expired - Fee Related
- 1990-09-18 EP EP94112143A patent/EP0643974B1/fr not_active Expired - Lifetime
- 1990-09-18 DE DE59010903T patent/DE59010903D1/de not_active Expired - Fee Related
- 1990-09-18 ES ES94112144T patent/ES2145077T3/es not_active Expired - Lifetime
- 1990-09-18 ES ES94112143T patent/ES2129551T3/es not_active Expired - Lifetime
- 1990-09-18 DE DE59010888T patent/DE59010888D1/de not_active Expired - Fee Related
- 1990-09-18 EP EP94112144A patent/EP0633313B1/fr not_active Expired - Lifetime
- 1990-09-18 YU YU177390A patent/YU48250B/sh unknown
- 1990-09-18 DK DK94112144T patent/DK0633313T3/da active
- 1990-09-18 PL PL90307358A patent/PL170229B1/pl not_active IP Right Cessation
- 1990-09-19 KR KR1019900014814A patent/KR100205462B1/ko not_active IP Right Cessation
- 1990-09-19 SK SK1510-98A patent/SK283088B6/sk unknown
- 1990-09-19 SK SK1511-98A patent/SK283089B6/sk unknown
- 1990-09-19 JP JP24765090A patent/JP3205932B2/ja not_active Expired - Fee Related
- 1990-09-19 CZ CZ95970A patent/CZ284616B6/cs not_active IP Right Cessation
- 1990-09-19 CZ CS904560A patent/CZ284538B6/cs not_active IP Right Cessation
- 1990-09-19 SK SK4560-90A patent/SK280285B6/sk unknown
- 1990-09-19 PT PT95349A patent/PT95349B/pt active IP Right Grant
- 1990-09-19 US US07/585,310 patent/US5178859A/en not_active Expired - Lifetime
-
1993
- 1993-05-27 US US08/068,063 patent/US5434077A/en not_active Expired - Fee Related
-
1994
- 1994-09-15 HR HR940545A patent/HRP940545B1/xx not_active IP Right Cessation
-
1995
- 1995-03-20 US US08/407,350 patent/US5686267A/en not_active Expired - Lifetime
- 1995-03-20 US US08/406,623 patent/US5780030A/en not_active Expired - Fee Related
- 1995-04-24 HU HU95P/P00108P patent/HU211228A9/hu unknown
-
1996
- 1996-02-14 GR GR960400397T patent/GR3018995T3/el unknown
-
1997
- 1997-03-12 YU YU9097A patent/YU49370B/sh unknown
-
1998
- 1998-02-13 HK HK98101147A patent/HK1002405A1/xx not_active IP Right Cessation
- 1998-02-23 US US09/027,843 patent/US5856447A/en not_active Expired - Fee Related
- 1998-08-29 KR KR1019980035375A patent/KR100202128B1/ko not_active IP Right Cessation
- 1998-12-23 HK HK98114958A patent/HK1013620A1/xx not_active IP Right Cessation
-
1999
- 1999-10-07 US US09/413,858 patent/US6613331B1/en not_active Expired - Fee Related
- 1999-11-30 GR GR990403104T patent/GR3032010T3/el unknown
-
2000
- 2000-06-14 GR GR20000401362T patent/GR3033675T3/el not_active IP Right Cessation
- 2000-07-26 JP JP2000225341A patent/JP3328644B2/ja not_active Expired - Fee Related
- 2000-12-11 JP JP2000376159A patent/JP3418171B2/ja not_active Expired - Fee Related
-
2001
- 2001-09-24 NO NO20014624A patent/NO315905B1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK283088B6 (sk) | Spôsob získania antigénu, ktorý imunologicky reaguje s protilátkami proti B burgdorferi antigénom a spôsob výroby vakcíny obsahujúcej takýto antigén | |
US5747294A (en) | Compositions and methods for the prevention and diagnosis of lyme disease | |
IE83320B1 (en) | Vaccine against lyme disease | |
US5807685A (en) | OspE, OspF, and S1 polypeptides in Borrelia burgdorferi | |
Jonson et al. | Epitope differences in toxin-coregulated pili produced by classical and El Tor Vibrio cholerae O1 | |
MX2010010614A (es) | Composiciones, metodos y kits. | |
US5543304A (en) | 43 Kd protein vaccine and method for the production thereof | |
AU673912B2 (en) | Vaccine against lyme disease | |
US6716591B1 (en) | B. burgdorferi polypeptides | |
IE83340B1 (en) | Vaccine against lyme disease |